This article is more than 5 years old. Information may no longer be current.

FDA accepts IND application for Nicox’s blepharitis treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has accepted an investigational new drug application for Nicox’s topical blepharitis treatment, the company announced in a press release.

NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals, is being developed as a targeted treatment of the eyelid margin for patients with acute exacerbations of blepharitis, the release said.

The company plans to announce a first-in-human, randomized, placebo-controlled, phase 2 clinical trial in the second half of this year.